Comprehensive Solutions for
STI Testing
STIs Impact the Health of Communities Across the USA
1 in 5
people have an STI on a any given day1
Many STIs present with similar symptoms but require different treatments.2 When left untreated, the long term implications can be serious:3
Estimated Prevalence of STIs in the United States1
Don’t Let Asymptomatic Become Problematic
Symptoms don’t necessarily correlate with patient harm, so screening for certain STIs is crucial.3
The CDC recommends NAAT as the preferred method for accurate chlamydia (CT) and gonorrhea (NG) screening of patients.2
- Asymptomatic STIs increase the potential for sustained transmission in the community.3
- Screening efforts for CT and NG focus on women between the age of 15–24 who identify as being sexually active.2,4-7
Market-Leading NAAT Solutions
Our broad array of highly sensitive NAATs accurately detect pathogens that cause STIs including chlamydia, gonorrhea, trichomoniasis, Mycoplasma genitalium and herpes simplex virus.
Aptima Combo 2® CT/NG Assay
Aptima Combo 2® CT/NG Assay
Simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae with high clinical sensitivity in asymptomatic and symptomatic patients.8
Aptima® Trichomonas vaginalis Assay
Aptima® Trichomonas vaginalis Assay
NAAT that offers superior sensitivity over wet mount or DNA probe method for detecting Trichomonas in women.9,10
Aptima® Mycoplasma genitalium Assay
Aptima® Mycoplasma genitalium Assay
FDA-cleared NAAT with up to 100% sensitivity to accurately identify M. gen11
Aptima® HSV 1 & 2 Assay
Aptima® HSV 1 & 2 Assay
Differentiates between HSV-1 and HSV-2 with high accuracy to support targeted counseling and management.12
Let’s Connect
Have a question or need to talk to a Hologic team member? We’re here to help.